BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

16 articles for C Phillips

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.EBI
Astrazeneca
Lead optimisation of pyrazoles as novel FPR1 antagonists.EBI
Astrazeneca
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.EBI
Pfizer
Sulfonamides as selective oestrogen receptorß agonists.EBI
Pfizer
Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors.EBI
Pfizer
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.EBI
Pfizer
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.EBI
Astrazeneca
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASEBI
Astrazeneca
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASEBI
Astrazeneca
Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.EBI
Astrazeneca
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASEBI
Astrazeneca
Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors.EBI
Astrazeneca
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.EBI
Pfizer
Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX.BDB
University of Namur
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.BDB
Bristol-Myers Squibb